B+
Bull case
0%
Probability
Target price
$5.00
+82.5% vs current
CLRB
Cellectar BiosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
1%
Probability
Target price
$2.80
+2.2% vs current
B-
Bear case
0%
Probability
Target price
$1.40
-48.9% vs current
AI sentiment snapshot
Latest data as of 2026-04-19
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+58.5
Score
AI commentary
This remains a cautious monitoring-style biotech memo rather than a high-conviction directional call. Primary sources support a real regulatory hook for iopofosine and a second, earlier-stage CLR 125 readout, but the deterministic prior is neutral, evidence quality is only middling, and catalyst density is low. The strongest fundamental fact is not just the EU filing path but also the financing clock: management's own filings indicate liquidity may not carry beyond the third quarter of 2026 without further action. That combination leaves CLRB with meaningful event upside but equally meaningful dilution and execution risk.
RankAlpha Sentiment Codex - 2026-04-19
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystMid-2026 early CLR 125 Phase 1b data in TNBCHigh impact
The March 4, 2026 corporate update said the CLR 125 Phase 1b dose-finding study in triple negative breast cancer has started, enrollment is ongoing, and early data are expected by mid-year 2026 [#8-K-2026-03-04]. Positive tolerability or early activity could help broaden the story beyond iopofosine, but this remains early-stage and likely secondary to the lead program.
2026-08-31catalystFinancing or strategic transaction before current cash runway expiresHigh impact
The 10-K states Cellectar had $13.2 million of cash at December 31, 2025, about $9.7 million of unrestricted cash at issuance, and may be unable to fund operations beyond the third quarter of 2026 without further action [#10-K-2026-03-04]. That makes a financing, licensing, or other liquidity event likely before the major regulatory path is fully de-risked.
2026-09-30eventEuropean CMA submission for iopofosine in Waldenstrom macroglobulinemiaHigh impact
Management said it is on track to submit a Conditional Marketing Authorization application to the EMA in Q3 2026, supported by 12-month CLOVER WaM follow-up, updated response data, PFS, duration of response, and post-BTKi subset analyses [#8-K-2026-03-04]. This is the clearest upside catalyst, but execution and regulator acceptance remain uncertain.
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-19 • Updated nightlySource: Internal modelMethodology